ARCHIVES

Gleevec Approval Sets Record For FDA Review: 73 Days

This article is from The Cancer Letter archive.

Vol. 24 No. 5 | May 25, 2001

Download PDF Visit The Full Archive

Related Articles

BRCA1 and BRCA2 Mutations Linked To Higher Survival

January 27, 2012

ACS Asks $1.5 Billion for NCI; Waxman Considers Requiring NIH To Send Budget Directly To Congress

March 4, 1983

Funding Opportunity: Leukemia & Lymphoma Society Launches Myeloid Program

October 31, 2014

Guest Editorial: Richard Schilsky Reflects On His Past Decade WithThe Board of Scientific Advisors

June 24, 2011

Nine Cancer Act Changes Considered By NCAB Subcommittee

September 3, 1976

DCT Program Cutbacks Planned as Research Stressed In 4 Cancers

February 26, 1993